H. Allgayer; M.M. Heiss; F.W. Schildberg· ISBN 9783642593499
Special offer terms
Zookal Study Premium
Subscribe & save
By selecting the 'Susbcribe & Save' option you are enrolling in an auto-renewing subscription of Zookal Study Premium. Cancel at anytime.
Auto-Renewal
Your Zookal Study Premium subscription will be renewed each month until you cancel. You consent to Zookal automatically charging your payment method on file NZ$19.99 each month after 1st month free period until you cancel.
How to Cancel
You can cancel your subscription anytime by visiting Manage account page, clicking "Manage subscription" and completing the steps to cancel. Cancellations take effect at the end of the 1st month free period (if applicable) or at the end of the current billing cycle in which your request to cancel was received. Subscription fees are not refundable.
Zookal Study Premium Monthly Subscription Includes:
Ability to post up to ten (10) questions per month.
20% off your textbooks order and free standard shipping whenever you shop online at
textbooks.zookal.co.nz
Unused monthly subscription benefits have no cash value, are not transferable, and expire at the end of each month. This means that subscription benefits do not roll over to or accumulate for use in subsequent months.
Payment Methods
Afterpay and Zip Pay will not be available for purchases with Zookal Study Premium subscription added to bag.
NZ$1.00 preauthorisation
You may see a NZ$1.00 preauthorisation by your bank which will disappear from your statement in a few business days..
Email communications
By adding Zookal Study Premium, you agree to receive email communications from Zookal.
An explosion of information has occurred since scientists began to define the molecular events that describe the malignant transformation and progression of cells and their development towards a life-threatening metastatic disease. The First International Congress on Molecular Staging of Cancer, held in Munich in December 2001, aimed to establish an international platform of exchange among molecular biologists, cell biologists, tumor immunologists, and clinical and surgical oncologists. This network approach should be fruitful for both clinicians and researchers. The highlighted topics included tumor-associated proteolysis, minimal residual disease, new approaches for molecular diagnosis and targeting, and the first molecular staging models. One session focused on technology transfer, opening up a new field of funding for innovative concepts. Finally, the impact of molecular staging on clinical strategies was discussed.